Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis. [electronic resource]
Producer: 20180223Description: 81090-81098 p. digitalISSN:- 1949-2553
- Adult
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents -- adverse effects
- Biomarkers, Tumor -- genetics
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Chi-Square Distribution
- Crizotinib
- Disease Progression
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Odds Ratio
- Protein Kinase Inhibitors -- adverse effects
- Pyrazoles -- adverse effects
- Pyridines -- adverse effects
- Receptor Protein-Tyrosine Kinases -- genetics
- Risk Factors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Meta-Analysis; Review
There are no comments on this title.
Log in to your account to post a comment.